IN THE UNITED STATES PATENT AND TRADEMARK OFFICE AS DESIGNATED/ELECTED OFFICE

Applicants:

Bhat, et al.

Int. Appln. No:

PCT/US03/18841

Int. Filing Date:

14 June 2003

US Appln. No.:

To Be Assigned

Case No.: 21057YP

Art Unit:

Filed:

Concurrently Herewith

Examiner:

For:

CARBOCYCLIC NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA

VIRAL POLYMERASE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to prosecution of the subject application. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Please amend this application as follows:

Amendments to the Specification are reflected on page 2 of this response. Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this response. Remarks begin on page 11 of this response.

DIPRESS MAIL CERTIFICATE

DATE OF DEPOSIT

27

EXPRESS MAIL NO. EV 42/2 4/163

THEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEI ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, RO. BOX 1450.

ALEXANDRIA, VIRGINA 22313-1450.

DATE